Blood Res 2020; 55(4):
Published online December 31, 2020
https://doi.org/10.5045/br.2020.2020255
© The Korean Society of Hematology
Correspondence to : Myung-Geun Shin, M.D., Ph.D.
Department of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun 58128, Korea
E-mail: mgshin@chonnam.ac.kr
#These authors contributed equally to this study.
Background
Chromosomal analysis is essential for the diagnosis and risk stratification of all leukemia patients. Not surprisingly, racial differences in chromosomal aberrations (CA) in hematological malignancies could be found, and CA incidence in leukemia might change over time, possibly due to environmental and lifestyle changes. Thus, we compared the frequency and range of CA in patients with acute leukemia (AL) during two time periods (2006‒2009 vs. 2010‒2015) and compared them with other prior studies.
Methods
We enrolled 717 patients with AL during a six-year period (2010‒2015). We compared the results to those of our earlier study (2006‒2009) [1]. Conventional cytogenetics, a multiplex reverse transcriptase (RT)-PCR system, and fluorescence
Results
The incidence of CA changed in the leukemia subgroups during the two time periods. Notably, the most frequent CA of childhood acute myeloid leukemia (AML) was
Conclusion
The distribution of CA in Korean AL patients changed over time in a single institute. This change might be due to environmental and lifestyle changes.
Keywords Acute leukemia, Chromosomal aberrations, Frequency, Spectra
Chromosomal aberrations (CA) in hematologic malignancies can be commonly examined using conventional cytogenetics, fluorescence
CA develops in almost 56% of adult
In total, 717 patients with AL were enrolled during a 6-year period (2010–2015). This study included 125 children (median age, 8 yr; range, 0–18 yr) and 592 adults (median age, 57 yr; range, 19–88 yr). A total of 66% (83/125) of the children were male and 34% (42/125) were female; 58% (341/592) of the adults were male and 42% (251/592) were female; 73% (521/717) were diagnosed with primary (84%) or secondary (16%) AML (40 children, 481 adults), 26% (187/717) were diagnosed with acute lymphoid leukemia (ALL) (80 children, 107 adults), and 1% (9/717) were diagnosed with mixed phenotype acute leukemia (MPAL) (Supplementary Table 1). Clinical and laboratory data, such as sex, age, and the results of multiplex RT-PCR, FISH, and conventional cytogenetics were obtained from electronic medical records (EMR). This study was approved by the institutional review board (CNUHH No. 2009-35). Informed consent was obtained from all participating patients.
In total, 89% (637/717) of AL patients were analyzed using the multiplex RT-PCR system. Briefly, RNA was extracted from the peripheral blood (PB) or bone marrow (BM) using a commercial kit (RNAqueous kit; Ambion, Austin, TX, USA), in accordance with the manufacturer’s protocol. The multiplex RT-PCR test kit (DNA Technology, Aarhus, Denmark) was used to detect 28 of the most common leukemic fusion genes and more than 80 splice variants (Supplementary Fig. 1).
FISH was performed in appropriate BM or PB specimens available from 609 patients, in addition to the conventional cytogenetic method. It was performed using an appropriate probe (Abbott Molecular/Vysis, Des Plaines, IL, USA), in accordance with the manufacturer’s instructions.
Conventional cytogenetic analysis was performed at the initial diagnosis phase using short-term cultures of BM cells. At least 20 metaphases were analyzed in each case, and the clonal CA was described according to the International System for Cytogenetic Nomenclature 2009 and 2013 (Supplementary Fig. 2).
Sixteen CA types were detected in 36% (228/637) of the patients using a multiplex RT-PCR system (Supplementary Table 2). The multiplex RT-PCR system detected fusion transcripts in 35% (159/460) of AML patients, 38% (64/168) of ALL patients, and 56% (5/9) of MPAL patients (Table 1).
Table 1 Frequency and spectra of chromosomal aberrations according to the type of all acute leukemia patients using the multiplex RT-PCR system.
Chromosomal aberration using multiplex RT-PCR system | Fusion transcript | AML | ALL | MPAL | Total |
---|---|---|---|---|---|
t(15;17)(q24;q21) | 67 | 67 | |||
t(9;22)(q34;q11) | 9 | 34 | 4 | 47 | |
t(8;21)(q22;q22) | 34 | 34 | |||
11q23 | |||||
t(4;11)(q21;q23) | 3 | 3 | |||
t(6;11)(q27;q23) | 5 | 5 | |||
t(11;19)(q23;p13.3) | 2 | 2 | |||
t(9;11)(p22;q23) | 8 | 1 | 9 | ||
t(10;11)(p12;q23) | 5 | 1 | 6 | ||
t(11;19)(q23;p13.3) | 1 | 1 | |||
t(12;21)(p13;q22) | 15 | 15 | |||
t(1;19)(q23;p13) | 5 | 5 | |||
inv(16)(p13;q22) | 23 | 23 | |||
t(9;9)(q34;q34) | 1 | 1 | 2 | ||
del(1p32) | 4 | 4 | |||
t(16;21)(p11;q22) | 3 | 3 | |||
t(6;9)(p23;q34) | 2 | 2 | |||
N of positive cases | 159 | 64 | 5 | 228 | |
Total cases | 521 | 187 | 9 | 717 | |
NT | 61 | 19 | 0 | 80 | |
Cases excluding ‘NT’ | 460 | 168 | 9 | 637 | |
Positive cases excluding ‘NT’ (%) | 35 | 38 | 56 | 36 |
Abbreviations: ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; MPAL, mixed-phenotype acute leukemia; NT, not tested.
In total, conventional cytogenetic methods were performed in 97% (506/521) of the AML patients, 94% (175/187) of the ALL patients, and 100% (9/9) of the MPAL patients. Among these, 93% of AML, 87% of ALL, and 100% of MPAL were successfully analyzed. Successful analyses were achieved in 92% (634/690) of the patients. Among the successfully analyzed cases, 59% (372/634) had detectable CA and 41% (262/634) were considered cytogenetically normal (Table 2).
Table 2 Frequency and spectra of chromosomal aberrations according to the type of acute leukemia and detection method in all patients using conventional cytogenetics, including FISH.
Chromosomal aberration by conventional cytogenetics | Fusion transcript | AML | ALL | MPAL | Total | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
K | F | K | F | K | F | ||||||
t(15;17)(q24;q21) | 54 | 13 | 67 | ||||||||
t(9;22)(q34;q11) | 3 | 4 | 22 | 8 | 4 | 41 | |||||
t(8;21)(q22;q22) | 36 | 36 | |||||||||
11q23 | |||||||||||
t(4;11)(q21;q23) | 1 | 1 | |||||||||
t(6;11)(q27;q23) | 5 | 5 | |||||||||
t(11;19)(q23;p13.3) | 0 | ||||||||||
t(9;11)(p22;q23) | 6 | 1 | 7 | ||||||||
t(10;11)(p12;q23) | 4 | 1 | 5 | ||||||||
t(11;19)(q23;p13.3) | 1 | 1 | |||||||||
t(12;21)(p13;q22) | 5 | 7 | 12 | ||||||||
t(1;19)(q23;p13) | 1 | 1 | |||||||||
inv(16)(p13;q22) | 21 | 1 | 22 | ||||||||
t(9;9)(q34;q34) | 0 | ||||||||||
del(1p32) | 0 | ||||||||||
t(16;21)(p11;q22) | 2 | 2 | |||||||||
t(6;9)(p23;q34) | 2 | 2 | |||||||||
Extra-aberrationa) | 113 | 5 | 43 | 7 | 2 | 170 | |||||
Positive cases excluding extra-aberration | 151 | 46 | 5 | 202 | |||||||
Positive cases | 269 | 96 | 7 | 372 | |||||||
Total cases | 521 | 187 | 9 | 717 | |||||||
Cases of ‘NT’ | 15 | 12 | 0 | 27 | |||||||
Cases excluding ‘NT’ | 506 | 175 | 9 | 690 | |||||||
Positive cases excluding ‘extra-aberration’ & ‘NT’ (%) | 30 | 26 | 56 | 29 | |||||||
Positive cases excluding ‘NT’ (%) | 53 | 55 | 78 | 54 |
a)Extra-aberrations are the numerical abnormalities or structural rearrangements, excluding 28 fusion transcripts of the multiplex RT-PCR system.
Abbreviations: F, fluorescence
Thirteen types of fusion transcripts, excluding extra-aberrations, were detected in 29% (202/690) of patients using conventional cytogenetics. Meanwhile, the extra-aberration indicated numerical abnormalities or structural rearrangements, excluding 28 fusion transcripts, in the multiplex RT-PCR system. The most frequent CA was t(15;17)(q24;q21) in 9.7% (67/690), followed by t(9;22) (q34;q11) in 5.9% (41/690), t(8;21)(q22;q22) in 5.2% (36/690), inv(16)(p13;q22) in 3.2% (22/690), and
A total of 46% percent (54/117) of the childhood group subjects exhibited a positive result using the multiplex RT-PCR system. Within a group of 65% (24/37) of childhood AML patients, the common CA included eight
In a group of 35% (159/460) of AML patients, the following fusion transcripts were detected: 67
There was an agreement between the multiplex RT-PCR system and conventional cytogenetics in 71% (394/553) of patients. No CA was detected using either method in 41% (228/553) of patients. Thirteen types of fusion transcripts were detected using a multiplex RT-PCR system in 30% (166/553) of the patients, which was in agreement with conventional cytogenetics. Conventional cytogenetics disclosed additional structural rearrangements and/or numerical abnormalities in 11% (61/553) of the patients with specific aberrations, which were demonstrated using both methods. The results of the multiplex RT-PCR system did not correspond with the conventional cytogenetics in 29% (159/553) of the patients. Cytogenetically cryptic translocations solely detected using multiplex RT-PCR system were present in 5% (28/553) of the patients with a normal karyotype, numerical abnormalities, or structural rearrangements based on conventional cytogenetics. Detailed comparison data between the multiplex RT-PCR system and conventional cytogenetics are summarized in Supplementary Table 6. A total of 36% (131/359) of the patients with a negative result based on the multiplex RT-PCR system had CA, according to conventional cytogenetics results (Supplementary Table 6–8).
Considering both PCR methods and conventional cytogenetics, the most frequent CA of childhood and adult AML was
In the current study, 98 types of CA were determined in 717 patients with hematological malignancies. The multiplex RT-PCR system for screening 28 fusion transcripts identified only 16 types among them. Eighty-two types of leukemic fusion could not be found using multiplex RT-PCR, excluding numerical abnormalities. Three important CAs, such as i(17)(q10), t(3;3)(q21;q26.2), and t(8;14)(q24;q32), were found using conventional cytogenetics (Supplementary Table 7, 8, Supplementary Fig. 2).
Considering the many fusion genes and breakpoint variants currently determined, more than 50 separate PCR reactions are required to screen an AL patient with a standard operation [9]. We adopted a commercially accessible multiplex-RT-PCR system (DNA Technology) to identify 28 common fusion genes and over 80 splice variants based on previous research [9]. Data from Denmark using this system, which was employed on specimens from 143 patients with a median age of 63 years (range, 0–85 yr; 132 adults, 11 children), revealed that CA was identified in only 15% (21/143) of the patients [10]. In contrast, this study showed a higher CA frequency of 36% (228/637), using the same multiplex RT-PCR system: 35% (159/460) of AML patients, 38% (64/168) of ALL patients, and 56% (5/9) of MPAL patients. The rate of occurrence and spread of leukemic fusion genes in AL also differed from earlier European data [10]. CA occurred in 65% (24/37) of childhood AML cases, whereas it only occurred in about 40% (24/60) of childhood AML cases based on the same multiplex RT-PCR system from Austria [11]. The frequency of leukemic fusion genes in our ALL patients (38%, 64/168) was analogous to an Italian dataset utilizing the same multiplex RT-PCR system: 37% (28/75) and 39% (36/93) of childhood and adult ALL patients, respectively. In the Italian study, 39% of 170 ALL patients carried leukemic fusion genes: 39% and 40% of the childhood and adult ALL patients, respectively [12].
The most common CA in AML patients was the t(15;17) abnormality (15%, 67/460). The occurrence rate was higher compared to data from other institutes of Korea (6.7%), Caucasian (6.5, 10%), Australian (12%), Japanese (11%), and Singapore-Chinese (11%), but it was analogous to the Chinese data (14.3%) [5, 6, 13]. This discrepancy may be due to the sample size and likely to ethnic differences. The geographic diversity of CA in leukemia needs further study and a better understanding of the genetic and environmental factors associated with leukemia. The frequency and range of CA in ALL were similar between this study and previous studies [6, 14]. A balanced translocation of the
The discrepancy of 29% (159/553) between the multiplex RT-PCR system and conventional cytogenetics was mainly due to numerical and submicroscopic anomalies. The multiplex RT-PCR system used to screen 28 fusion transcripts identified 16 types in the group of 98 types of CA determined in 717 patients with leukemia. The concordance rate of 71% (394/553) between the multiplex RT-PCR system and conventional karyotyping was analogous to an earlier study (70%) [1].
Choi
In addition, the range or spectra of leukemic fusion genes in AL differed from a prior report in Korea (Fig. 1, 2) [1]. In a prior study, Choi
In addition, the most prevalent CA in childhood AML patients was
Interestingly, there were cases with significant CA, such as i(17)(q10), t(3;3)(q21;q26.2), and t(8;14)(q24;q32), that were not identified using the commercial multiplex RT-PCR system (Supplementary Table 8, Supplementary Fig. 2). These are very meaningful and typical CA in hematological malignancies, such as AL. t(8;14)(q24;q32) is a typical CA in patients with ALL (Burkitt type), and the t(3;3)(q21;q26.2) is a newly adopted recurrent CA in AML patients, in accordance with the 2008 WHO classification [1]. In addition, i(17)(q10) is repeatedly shown in the blast crisis of Philadelphia- positive CML patients. As a solitary CA, i(17q) has also been demonstrated in primary fibrosis, hypereosinophilic syndrome, and rare cases of myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN) that result in acute non-lymphocytic leukemia. In accordance with several studies, MDS/MPN, which contains the i(17q) as a single CA, is regarded as a distinctive entity with a frequency of 0.4–1.57% of MDS, or 1% of all myeloid cases, which features a male predominance, significant anemia, hyposegmented neutrophils, increased micromegakaryocytes, and an unfavorable prognosis [18, 19]. Thus, it is worth considering CA as an additional screening panel of leukemic fusion genes for improving the molecular detection system.
In conclusion, this study disclosed the frequency and range of CA in Korean AL patients, which differed from those of previous published reports. This change might be due to environmental and lifestyle changes [7, 8]. Our data were collected from a single center in Korea; thus, the findings may not be generalizable to other institutions. In addition, the limited number of patients might preclude definitive conclusions on the AL changes in Korea. Further studies to accumulate more evidence are needed to determine the change in spectra or range of AL. Nonetheless, this study might provide important information for improving the molecular detection system in Korean AL patients.
MGS designed the study. JHP and YEL enrolled the patients, collected clinical laboratory data, and performed laboratory measurements. HRK initially set up a multiplex RT-PCR detection system. JHP wrote the preliminary manuscript. MGS, JHP, and MGK analyzed the data. MGK, MGS, and HRK revised the manuscript. JHL, HJC, and JHS interpreted the data and provided valuable comments and recommendations. All the authors have revised and accepted the final version of the manuscript.
No potential conflicts of interest relevant to this article were reported.
Blood Res 2020; 55(4): 225-245
Published online December 31, 2020 https://doi.org/10.5045/br.2020.2020255
Copyright © The Korean Society of Hematology.
Je-Hyun Park1,2,#, Min-Gu Kang3,#, Hye-Ran Kim4,#, Young-Eun Lee2, Jun Hyung Lee1, Hyun-Jung Choi1, Jong-Hee Shin1, Myung-Geun Shin1,2
1Department of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, 2Brain Korea 21 Plus program, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun, 3Department of Laboratory Medicine, GwangYang Sarang General Hospital, Gwangyang, 4College of Korean Medicine, Dongshin University, Naju, Korea
Correspondence to:Myung-Geun Shin, M.D., Ph.D.
Department of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun 58128, Korea
E-mail: mgshin@chonnam.ac.kr
#These authors contributed equally to this study.
Background
Chromosomal analysis is essential for the diagnosis and risk stratification of all leukemia patients. Not surprisingly, racial differences in chromosomal aberrations (CA) in hematological malignancies could be found, and CA incidence in leukemia might change over time, possibly due to environmental and lifestyle changes. Thus, we compared the frequency and range of CA in patients with acute leukemia (AL) during two time periods (2006‒2009 vs. 2010‒2015) and compared them with other prior studies.
Methods
We enrolled 717 patients with AL during a six-year period (2010‒2015). We compared the results to those of our earlier study (2006‒2009) [1]. Conventional cytogenetics, a multiplex reverse transcriptase (RT)-PCR system, and fluorescence
Results
The incidence of CA changed in the leukemia subgroups during the two time periods. Notably, the most frequent CA of childhood acute myeloid leukemia (AML) was
Conclusion
The distribution of CA in Korean AL patients changed over time in a single institute. This change might be due to environmental and lifestyle changes.
Keywords: Acute leukemia, Chromosomal aberrations, Frequency, Spectra
Chromosomal aberrations (CA) in hematologic malignancies can be commonly examined using conventional cytogenetics, fluorescence
CA develops in almost 56% of adult
In total, 717 patients with AL were enrolled during a 6-year period (2010–2015). This study included 125 children (median age, 8 yr; range, 0–18 yr) and 592 adults (median age, 57 yr; range, 19–88 yr). A total of 66% (83/125) of the children were male and 34% (42/125) were female; 58% (341/592) of the adults were male and 42% (251/592) were female; 73% (521/717) were diagnosed with primary (84%) or secondary (16%) AML (40 children, 481 adults), 26% (187/717) were diagnosed with acute lymphoid leukemia (ALL) (80 children, 107 adults), and 1% (9/717) were diagnosed with mixed phenotype acute leukemia (MPAL) (Supplementary Table 1). Clinical and laboratory data, such as sex, age, and the results of multiplex RT-PCR, FISH, and conventional cytogenetics were obtained from electronic medical records (EMR). This study was approved by the institutional review board (CNUHH No. 2009-35). Informed consent was obtained from all participating patients.
In total, 89% (637/717) of AL patients were analyzed using the multiplex RT-PCR system. Briefly, RNA was extracted from the peripheral blood (PB) or bone marrow (BM) using a commercial kit (RNAqueous kit; Ambion, Austin, TX, USA), in accordance with the manufacturer’s protocol. The multiplex RT-PCR test kit (DNA Technology, Aarhus, Denmark) was used to detect 28 of the most common leukemic fusion genes and more than 80 splice variants (Supplementary Fig. 1).
FISH was performed in appropriate BM or PB specimens available from 609 patients, in addition to the conventional cytogenetic method. It was performed using an appropriate probe (Abbott Molecular/Vysis, Des Plaines, IL, USA), in accordance with the manufacturer’s instructions.
Conventional cytogenetic analysis was performed at the initial diagnosis phase using short-term cultures of BM cells. At least 20 metaphases were analyzed in each case, and the clonal CA was described according to the International System for Cytogenetic Nomenclature 2009 and 2013 (Supplementary Fig. 2).
Sixteen CA types were detected in 36% (228/637) of the patients using a multiplex RT-PCR system (Supplementary Table 2). The multiplex RT-PCR system detected fusion transcripts in 35% (159/460) of AML patients, 38% (64/168) of ALL patients, and 56% (5/9) of MPAL patients (Table 1).
Table 1 . Frequency and spectra of chromosomal aberrations according to the type of all acute leukemia patients using the multiplex RT-PCR system..
Chromosomal aberration using multiplex RT-PCR system | Fusion transcript | AML | ALL | MPAL | Total |
---|---|---|---|---|---|
t(15;17)(q24;q21) | 67 | 67 | |||
t(9;22)(q34;q11) | 9 | 34 | 4 | 47 | |
t(8;21)(q22;q22) | 34 | 34 | |||
11q23 | |||||
t(4;11)(q21;q23) | 3 | 3 | |||
t(6;11)(q27;q23) | 5 | 5 | |||
t(11;19)(q23;p13.3) | 2 | 2 | |||
t(9;11)(p22;q23) | 8 | 1 | 9 | ||
t(10;11)(p12;q23) | 5 | 1 | 6 | ||
t(11;19)(q23;p13.3) | 1 | 1 | |||
t(12;21)(p13;q22) | 15 | 15 | |||
t(1;19)(q23;p13) | 5 | 5 | |||
inv(16)(p13;q22) | 23 | 23 | |||
t(9;9)(q34;q34) | 1 | 1 | 2 | ||
del(1p32) | 4 | 4 | |||
t(16;21)(p11;q22) | 3 | 3 | |||
t(6;9)(p23;q34) | 2 | 2 | |||
N of positive cases | 159 | 64 | 5 | 228 | |
Total cases | 521 | 187 | 9 | 717 | |
NT | 61 | 19 | 0 | 80 | |
Cases excluding ‘NT’ | 460 | 168 | 9 | 637 | |
Positive cases excluding ‘NT’ (%) | 35 | 38 | 56 | 36 |
Abbreviations: ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; MPAL, mixed-phenotype acute leukemia; NT, not tested..
In total, conventional cytogenetic methods were performed in 97% (506/521) of the AML patients, 94% (175/187) of the ALL patients, and 100% (9/9) of the MPAL patients. Among these, 93% of AML, 87% of ALL, and 100% of MPAL were successfully analyzed. Successful analyses were achieved in 92% (634/690) of the patients. Among the successfully analyzed cases, 59% (372/634) had detectable CA and 41% (262/634) were considered cytogenetically normal (Table 2).
Table 2 . Frequency and spectra of chromosomal aberrations according to the type of acute leukemia and detection method in all patients using conventional cytogenetics, including FISH..
Chromosomal aberration by conventional cytogenetics | Fusion transcript | AML | ALL | MPAL | Total | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
K | F | K | F | K | F | ||||||
t(15;17)(q24;q21) | 54 | 13 | 67 | ||||||||
t(9;22)(q34;q11) | 3 | 4 | 22 | 8 | 4 | 41 | |||||
t(8;21)(q22;q22) | 36 | 36 | |||||||||
11q23 | |||||||||||
t(4;11)(q21;q23) | 1 | 1 | |||||||||
t(6;11)(q27;q23) | 5 | 5 | |||||||||
t(11;19)(q23;p13.3) | 0 | ||||||||||
t(9;11)(p22;q23) | 6 | 1 | 7 | ||||||||
t(10;11)(p12;q23) | 4 | 1 | 5 | ||||||||
t(11;19)(q23;p13.3) | 1 | 1 | |||||||||
t(12;21)(p13;q22) | 5 | 7 | 12 | ||||||||
t(1;19)(q23;p13) | 1 | 1 | |||||||||
inv(16)(p13;q22) | 21 | 1 | 22 | ||||||||
t(9;9)(q34;q34) | 0 | ||||||||||
del(1p32) | 0 | ||||||||||
t(16;21)(p11;q22) | 2 | 2 | |||||||||
t(6;9)(p23;q34) | 2 | 2 | |||||||||
Extra-aberrationa) | 113 | 5 | 43 | 7 | 2 | 170 | |||||
Positive cases excluding extra-aberration | 151 | 46 | 5 | 202 | |||||||
Positive cases | 269 | 96 | 7 | 372 | |||||||
Total cases | 521 | 187 | 9 | 717 | |||||||
Cases of ‘NT’ | 15 | 12 | 0 | 27 | |||||||
Cases excluding ‘NT’ | 506 | 175 | 9 | 690 | |||||||
Positive cases excluding ‘extra-aberration’ & ‘NT’ (%) | 30 | 26 | 56 | 29 | |||||||
Positive cases excluding ‘NT’ (%) | 53 | 55 | 78 | 54 |
a)Extra-aberrations are the numerical abnormalities or structural rearrangements, excluding 28 fusion transcripts of the multiplex RT-PCR system..
Abbreviations: F, fluorescence
Thirteen types of fusion transcripts, excluding extra-aberrations, were detected in 29% (202/690) of patients using conventional cytogenetics. Meanwhile, the extra-aberration indicated numerical abnormalities or structural rearrangements, excluding 28 fusion transcripts, in the multiplex RT-PCR system. The most frequent CA was t(15;17)(q24;q21) in 9.7% (67/690), followed by t(9;22) (q34;q11) in 5.9% (41/690), t(8;21)(q22;q22) in 5.2% (36/690), inv(16)(p13;q22) in 3.2% (22/690), and
A total of 46% percent (54/117) of the childhood group subjects exhibited a positive result using the multiplex RT-PCR system. Within a group of 65% (24/37) of childhood AML patients, the common CA included eight
In a group of 35% (159/460) of AML patients, the following fusion transcripts were detected: 67
There was an agreement between the multiplex RT-PCR system and conventional cytogenetics in 71% (394/553) of patients. No CA was detected using either method in 41% (228/553) of patients. Thirteen types of fusion transcripts were detected using a multiplex RT-PCR system in 30% (166/553) of the patients, which was in agreement with conventional cytogenetics. Conventional cytogenetics disclosed additional structural rearrangements and/or numerical abnormalities in 11% (61/553) of the patients with specific aberrations, which were demonstrated using both methods. The results of the multiplex RT-PCR system did not correspond with the conventional cytogenetics in 29% (159/553) of the patients. Cytogenetically cryptic translocations solely detected using multiplex RT-PCR system were present in 5% (28/553) of the patients with a normal karyotype, numerical abnormalities, or structural rearrangements based on conventional cytogenetics. Detailed comparison data between the multiplex RT-PCR system and conventional cytogenetics are summarized in Supplementary Table 6. A total of 36% (131/359) of the patients with a negative result based on the multiplex RT-PCR system had CA, according to conventional cytogenetics results (Supplementary Table 6–8).
Considering both PCR methods and conventional cytogenetics, the most frequent CA of childhood and adult AML was
In the current study, 98 types of CA were determined in 717 patients with hematological malignancies. The multiplex RT-PCR system for screening 28 fusion transcripts identified only 16 types among them. Eighty-two types of leukemic fusion could not be found using multiplex RT-PCR, excluding numerical abnormalities. Three important CAs, such as i(17)(q10), t(3;3)(q21;q26.2), and t(8;14)(q24;q32), were found using conventional cytogenetics (Supplementary Table 7, 8, Supplementary Fig. 2).
Considering the many fusion genes and breakpoint variants currently determined, more than 50 separate PCR reactions are required to screen an AL patient with a standard operation [9]. We adopted a commercially accessible multiplex-RT-PCR system (DNA Technology) to identify 28 common fusion genes and over 80 splice variants based on previous research [9]. Data from Denmark using this system, which was employed on specimens from 143 patients with a median age of 63 years (range, 0–85 yr; 132 adults, 11 children), revealed that CA was identified in only 15% (21/143) of the patients [10]. In contrast, this study showed a higher CA frequency of 36% (228/637), using the same multiplex RT-PCR system: 35% (159/460) of AML patients, 38% (64/168) of ALL patients, and 56% (5/9) of MPAL patients. The rate of occurrence and spread of leukemic fusion genes in AL also differed from earlier European data [10]. CA occurred in 65% (24/37) of childhood AML cases, whereas it only occurred in about 40% (24/60) of childhood AML cases based on the same multiplex RT-PCR system from Austria [11]. The frequency of leukemic fusion genes in our ALL patients (38%, 64/168) was analogous to an Italian dataset utilizing the same multiplex RT-PCR system: 37% (28/75) and 39% (36/93) of childhood and adult ALL patients, respectively. In the Italian study, 39% of 170 ALL patients carried leukemic fusion genes: 39% and 40% of the childhood and adult ALL patients, respectively [12].
The most common CA in AML patients was the t(15;17) abnormality (15%, 67/460). The occurrence rate was higher compared to data from other institutes of Korea (6.7%), Caucasian (6.5, 10%), Australian (12%), Japanese (11%), and Singapore-Chinese (11%), but it was analogous to the Chinese data (14.3%) [5, 6, 13]. This discrepancy may be due to the sample size and likely to ethnic differences. The geographic diversity of CA in leukemia needs further study and a better understanding of the genetic and environmental factors associated with leukemia. The frequency and range of CA in ALL were similar between this study and previous studies [6, 14]. A balanced translocation of the
The discrepancy of 29% (159/553) between the multiplex RT-PCR system and conventional cytogenetics was mainly due to numerical and submicroscopic anomalies. The multiplex RT-PCR system used to screen 28 fusion transcripts identified 16 types in the group of 98 types of CA determined in 717 patients with leukemia. The concordance rate of 71% (394/553) between the multiplex RT-PCR system and conventional karyotyping was analogous to an earlier study (70%) [1].
Choi
In addition, the range or spectra of leukemic fusion genes in AL differed from a prior report in Korea (Fig. 1, 2) [1]. In a prior study, Choi
In addition, the most prevalent CA in childhood AML patients was
Interestingly, there were cases with significant CA, such as i(17)(q10), t(3;3)(q21;q26.2), and t(8;14)(q24;q32), that were not identified using the commercial multiplex RT-PCR system (Supplementary Table 8, Supplementary Fig. 2). These are very meaningful and typical CA in hematological malignancies, such as AL. t(8;14)(q24;q32) is a typical CA in patients with ALL (Burkitt type), and the t(3;3)(q21;q26.2) is a newly adopted recurrent CA in AML patients, in accordance with the 2008 WHO classification [1]. In addition, i(17)(q10) is repeatedly shown in the blast crisis of Philadelphia- positive CML patients. As a solitary CA, i(17q) has also been demonstrated in primary fibrosis, hypereosinophilic syndrome, and rare cases of myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN) that result in acute non-lymphocytic leukemia. In accordance with several studies, MDS/MPN, which contains the i(17q) as a single CA, is regarded as a distinctive entity with a frequency of 0.4–1.57% of MDS, or 1% of all myeloid cases, which features a male predominance, significant anemia, hyposegmented neutrophils, increased micromegakaryocytes, and an unfavorable prognosis [18, 19]. Thus, it is worth considering CA as an additional screening panel of leukemic fusion genes for improving the molecular detection system.
In conclusion, this study disclosed the frequency and range of CA in Korean AL patients, which differed from those of previous published reports. This change might be due to environmental and lifestyle changes [7, 8]. Our data were collected from a single center in Korea; thus, the findings may not be generalizable to other institutions. In addition, the limited number of patients might preclude definitive conclusions on the AL changes in Korea. Further studies to accumulate more evidence are needed to determine the change in spectra or range of AL. Nonetheless, this study might provide important information for improving the molecular detection system in Korean AL patients.
MGS designed the study. JHP and YEL enrolled the patients, collected clinical laboratory data, and performed laboratory measurements. HRK initially set up a multiplex RT-PCR detection system. JHP wrote the preliminary manuscript. MGS, JHP, and MGK analyzed the data. MGK, MGS, and HRK revised the manuscript. JHL, HJC, and JHS interpreted the data and provided valuable comments and recommendations. All the authors have revised and accepted the final version of the manuscript.
No potential conflicts of interest relevant to this article were reported.
Table 1 . Frequency and spectra of chromosomal aberrations according to the type of all acute leukemia patients using the multiplex RT-PCR system..
Chromosomal aberration using multiplex RT-PCR system | Fusion transcript | AML | ALL | MPAL | Total |
---|---|---|---|---|---|
t(15;17)(q24;q21) | 67 | 67 | |||
t(9;22)(q34;q11) | 9 | 34 | 4 | 47 | |
t(8;21)(q22;q22) | 34 | 34 | |||
11q23 | |||||
t(4;11)(q21;q23) | 3 | 3 | |||
t(6;11)(q27;q23) | 5 | 5 | |||
t(11;19)(q23;p13.3) | 2 | 2 | |||
t(9;11)(p22;q23) | 8 | 1 | 9 | ||
t(10;11)(p12;q23) | 5 | 1 | 6 | ||
t(11;19)(q23;p13.3) | 1 | 1 | |||
t(12;21)(p13;q22) | 15 | 15 | |||
t(1;19)(q23;p13) | 5 | 5 | |||
inv(16)(p13;q22) | 23 | 23 | |||
t(9;9)(q34;q34) | 1 | 1 | 2 | ||
del(1p32) | 4 | 4 | |||
t(16;21)(p11;q22) | 3 | 3 | |||
t(6;9)(p23;q34) | 2 | 2 | |||
N of positive cases | 159 | 64 | 5 | 228 | |
Total cases | 521 | 187 | 9 | 717 | |
NT | 61 | 19 | 0 | 80 | |
Cases excluding ‘NT’ | 460 | 168 | 9 | 637 | |
Positive cases excluding ‘NT’ (%) | 35 | 38 | 56 | 36 |
Abbreviations: ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; MPAL, mixed-phenotype acute leukemia; NT, not tested..
Table 2 . Frequency and spectra of chromosomal aberrations according to the type of acute leukemia and detection method in all patients using conventional cytogenetics, including FISH..
Chromosomal aberration by conventional cytogenetics | Fusion transcript | AML | ALL | MPAL | Total | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
K | F | K | F | K | F | ||||||
t(15;17)(q24;q21) | 54 | 13 | 67 | ||||||||
t(9;22)(q34;q11) | 3 | 4 | 22 | 8 | 4 | 41 | |||||
t(8;21)(q22;q22) | 36 | 36 | |||||||||
11q23 | |||||||||||
t(4;11)(q21;q23) | 1 | 1 | |||||||||
t(6;11)(q27;q23) | 5 | 5 | |||||||||
t(11;19)(q23;p13.3) | 0 | ||||||||||
t(9;11)(p22;q23) | 6 | 1 | 7 | ||||||||
t(10;11)(p12;q23) | 4 | 1 | 5 | ||||||||
t(11;19)(q23;p13.3) | 1 | 1 | |||||||||
t(12;21)(p13;q22) | 5 | 7 | 12 | ||||||||
t(1;19)(q23;p13) | 1 | 1 | |||||||||
inv(16)(p13;q22) | 21 | 1 | 22 | ||||||||
t(9;9)(q34;q34) | 0 | ||||||||||
del(1p32) | 0 | ||||||||||
t(16;21)(p11;q22) | 2 | 2 | |||||||||
t(6;9)(p23;q34) | 2 | 2 | |||||||||
Extra-aberrationa) | 113 | 5 | 43 | 7 | 2 | 170 | |||||
Positive cases excluding extra-aberration | 151 | 46 | 5 | 202 | |||||||
Positive cases | 269 | 96 | 7 | 372 | |||||||
Total cases | 521 | 187 | 9 | 717 | |||||||
Cases of ‘NT’ | 15 | 12 | 0 | 27 | |||||||
Cases excluding ‘NT’ | 506 | 175 | 9 | 690 | |||||||
Positive cases excluding ‘extra-aberration’ & ‘NT’ (%) | 30 | 26 | 56 | 29 | |||||||
Positive cases excluding ‘NT’ (%) | 53 | 55 | 78 | 54 |
a)Extra-aberrations are the numerical abnormalities or structural rearrangements, excluding 28 fusion transcripts of the multiplex RT-PCR system..
Abbreviations: F, fluorescence
Sung-Soo Park, Hee-Je Kim, Tong Yoon Kim, Joon yeop Lee, Jong Hyuk Lee, Gi June Min, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Dong-Wook Kim
Blood Res 2021; 56(3): 184-196Je-Hwan Lee, Sung-Soo Yoon, Chul Won Jung, Jung-Hee Lee, Dae-Young Kim, Young-Shin Lee, Sung Cheol Yun, Inho Kim, Seonyang Park, Byoung Kook Kim, Kihyun Kim, Jin Seok Ahn, and Kyoo-Hyung Lee
Korean J Hematol 2010; 45(2): 95-101Seong Hyun Jeong, Hyun Woo Lee, Seok Yun Kang, Mi Sun Ahn, Yoon Ho Hwang, Jin Hyuk Choi, Hugh Chul Kim, Sung Ran Cho, Joon Seong Park
Korean J Hematol 2009; 44(2): 67-73